Abstract CT150: A first-in-human phase I study of the OX40 agonist GSK3174998 (GSK998) +/- pembrolizumab in patients (Pts) with selected advanced solid tumors (ENGAGE-1) von Postel-Vinay, Sophie, Lam, Vincent K., Ros, Willeke, Bauer, Todd M., Hansen, Aaron R., Cho, Daniel C., Hodi, F. Stephen, Schellens, Jan H.M., Litton, Jennifer K., Aspeslagh, Sandrine, Autio, Karen A., Opdam, Frans L., McKean, Meredith, Somaiah, Neeta, Champiat, Stephane, Altan, Mehmet, Spreafico, Anna, Rahma, Osama, Paul, Elaine M., Ahlers, Christoph M., Zhou, Helen, Struemper, Herbert, Gorman, Shelby A., Watmuff, Maura, Yablonski, Kaitlin M., Yanamandra, Niranjan, Chisamore, Michael J., Schmidt, Emmett V., Hoos, Axel, Marabelle, Aurélien, Weber, Jeffrey S., Heymach, John V.

Volltext

First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1) von Postel-Vinay, Sophie, Lam, Vincent K, Ros, Willeke, Bauer, Todd M, Hansen, Aaron R, Cho, Daniel C, Stephen Hodi, F, Schellens, Jan H M, Litton, Jennifer K, Aspeslagh, Sandrine, Autio, Karen A, Opdam, Frans L, McKean, Meredith, Somaiah, Neeta, Champiat, Stephane, Altan, Mehmet, Spreafico, Anna, Rahma, Osama, Paul, Elaine M, Ahlers, Christoph M, Zhou, Helen, Struemper, Herbert, Gorman, Shelby A, Watmuff, Maura, Yablonski, Kaitlin M, Yanamandra, Niranjan, Chisamore, Michael J, Schmidt, Emmett V, Hoos, Axel, Marabelle, Aurelien, Weber, Jeffrey S, Heymach, John V

Volltext

Abstract CT124: A first-in-clinic phase 1 study of GSK3745417 STING agonist in relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome von Montesinos, Pau, Al-Ali, Haifa, Alonso-Dominguez, Juan M., Jentzsch, Madlen, Jongen-Lavrencic, Mojca, Martelli, Maria Paola, Röllig, Christoph, Sica, Simona, Iadevaia, Riham, Yablonski, Kaitlin, Wang, Tianli, Mahmood, Zafar, Koenen, Giedre, Schmidt, Hank, Yang, Jingsong, Yee, Karen

Volltext